Stock HINOON HIGHNOON LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Highnoon Laboratories Limited

Equities

HINOON

PK0070701013

Pharmaceuticals

End-of-day quote Pakistan S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
577.4 PKR +3.93% Intraday chart for Highnoon Laboratories Limited +9.16% +14.44%
Apr. 09 Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 9,945 16,907 20,762 23,906 22,624 26,733
Enterprise Value (EV) 1 9,326 16,200 19,350 21,404 21,785 25,855
P/E ratio 13.6 x 16.9 x 14.1 x 12.9 x 9.15 x 10.9 x
Yield 3.74% 2.42% 2.5% 3.19% 3.7% 5.95%
Capitalization / Revenue 1.33 x 1.87 x 1.94 x 1.84 x 1.43 x 1.35 x
EV / Revenue 1.24 x 1.79 x 1.81 x 1.65 x 1.38 x 1.31 x
EV / EBITDA 7.79 x 11.3 x 9.37 x 8.63 x 6.42 x 7.23 x
EV / FCF 32.1 x 52.8 x 23.5 x 18.3 x -14.7 x 40.8 x
FCF Yield 3.12% 1.89% 4.25% 5.48% -6.79% 2.45%
Price to Book 3.49 x 4.9 x 4.52 x 4.04 x 2.96 x 2.66 x
Nbr of stocks (in thousands) 52,983 52,983 52,983 52,983 52,983 52,983
Reference price 2 187.7 319.1 391.9 451.2 427.0 504.6
Announcement Date 4/5/19 4/21/20 4/1/21 3/28/22 4/14/23 4/9/24
1PKR in Million2PKR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 7,503 9,048 10,698 13,001 15,816 19,766
EBITDA 1 1,197 1,435 2,066 2,480 3,392 3,576
EBIT 1 1,066 1,321 1,937 2,313 3,209 3,378
Operating Margin 14.21% 14.6% 18.1% 17.79% 20.29% 17.09%
Earnings before Tax (EBT) 1 1,066 1,369 1,999 2,436 3,445 3,359
Net income 1 732.2 1,001 1,474 1,856 2,473 2,448
Net margin 9.76% 11.06% 13.78% 14.28% 15.63% 12.38%
EPS 2 13.82 18.89 27.82 35.04 46.67 46.20
Free Cash Flow 1 290.9 306.7 822.7 1,172 -1,480 634.5
FCF margin 3.88% 3.39% 7.69% 9.02% -9.36% 3.21%
FCF Conversion (EBITDA) 24.29% 21.37% 39.83% 47.27% - 17.74%
FCF Conversion (Net income) 39.73% 30.65% 55.82% 63.14% - 25.92%
Dividend per Share 2 7.019 7.721 9.800 14.37 15.81 30.00
Announcement Date 4/5/19 4/21/20 4/1/21 3/28/22 4/14/23 4/9/24
1PKR in Million2PKR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 620 706 1,412 2,502 838 878
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 291 307 823 1,172 -1,480 634
ROE (net income / shareholders' equity) 28% 31.8% 36.7% 35.3% 36.4% 27.7%
ROA (Net income/ Total Assets) 18.2% 19.2% 21.3% 19.1% 20.7% 16.4%
Assets 1 4,016 5,201 6,924 9,712 11,925 14,898
Book Value Per Share 2 53.70 65.10 86.70 112.0 144.0 189.0
Cash Flow per Share 2 14.70 16.20 16.20 15.40 8.170 4.010
Capex 1 113 265 367 278 835 788
Capex / Sales 1.51% 2.92% 3.43% 2.14% 5.28% 3.98%
Announcement Date 4/5/19 4/21/20 4/1/21 3/28/22 4/14/23 4/9/24
1PKR in Million2PKR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
HIGHNOON LABORATORIES LIMITED Stock Highnoon Laboratories Limited
+14.44% 110M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HINOON Stock
  4. Financials Highnoon Laboratories Limited